TAT and neoplasm: While A86 was composed of a 16-residue sequence designed as an interleukin-4 receptor-specific targeting ligand (IL4RP1, AP1) for the purpose of tumor-specific delivery, the inclusion of Tat ensured the efficient and direct delivery of miRNA genes to the cytosol.